Parkinson's Disease and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 19 records for MSC in Parkinson's Disease: 1 recruiting now, 1 labelled Phase 3 or 4, across 8 countries. Snapshot 2026-08-29.
Why this is studied in Parkinson's Disease
Parkinson's involves loss of dopaminergic neurons in the substantia nigra, making it one of the few neurodegenerative conditions with a defined cell type to replace. Pluripotent-derived dopaminergic grafts are a serious, decades-long research programme with surgical delivery — categorically different from intravenous infusions marketed for Parkinson's.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (parkinson disease x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 19 |
| Interventional studies in the sample | 16 |
| Recruiting right now | 1 |
| Completed | 4 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 or Phase 4 records | 1 |
| Countries with at least one site | 8 |
| Median planned enrolment | 20 participants |
| Largest single planned enrolment | 120 participants |
| First / most recent start year | 2009 — 2026 |
How mature is this evidence?
The ladder is partly climbed: 1 confirmatory-phase records against 19 in total, with the remainder concentrated in dose-finding and safety territory.
Registrations do not all survive contact with recruitment — 4 completed here, 1 stopped early, giving a 5% attrition rate.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 9 | 39% |
| Phase 2 | 8 | 35% |
| Not applicable | 5 | 22% |
| Phase 3 | 1 | 4% |
Median planned enrolment is 20 participants (largest single study: 120). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 8 countries with registered sites, United States dominates at roughly 40% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| United States | 6 |
| China | 3 |
| Belarus | 1 |
| Poland | 1 |
| Indonesia | 1 |
| India | 1 |
| Antigua and Barbuda | 1 |
| Jordan | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Lead sponsors split roughly 7 academic or hospital against 3 commercial — a academic profile. Commercial sponsorship is not a red flag by itself, but it changes publication incentives.
- Hope Biosciences Research Foundation — 4 records
- The University of Texas Health Science Center, Houston — 2 records
- Taiwan Mitochondrion Applied Technology Co., Ltd. — 1 record
- Belarusian Medical Academy of Post-Graduate Education — 1 record
- Hebei Newtherapy BIo-Pharma technology Co., Ltd. — 1 record
- Biocells Medical — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05152394 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2024-08-17 |
| NCT04146519 — Parkinson's Disease Therapy Using Cell Technology | Phase 2, Phase 3 | Unknown | 50 | Belarusian Medical Academy of Post-Graduate Education | 2017-07-01 |
| NCT07471230 — Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism | Phase 2 | Not Yet Recruiting | 120 | Biocells Medical | 2026-11-23 |
| NCT06858254 — Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism | Phase 1, Phase 2 | Not Yet Recruiting | 60 | Apeiron Research Center | 2025-04-01 |
| NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) | Phase 2 | Completed | 24 | Hope Biosciences Research Foundation | 2021-06-28 |
| NCT04995081 — Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) | Phase 2 | Completed | 60 | Hope Biosciences Research Foundation | 2021-07-16 |
| NCT04506073 — Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease | Phase 2 | Completed | 45 | The University of Texas Health Science Center, Houston | 2020-11-09 |
| NCT03684122 — Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD). | Phase 1, Phase 2 | Unknown | 10 | University of Jordan | 2018-06-01 |
| NCT01446614 — Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease | Phase 1, Phase 2 | Unknown | 20 | Guangzhou General Hospital of Guangzhou Military Command | 2011-10 |
| NCT05094011 — Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease | Phase 1 | Not Yet Recruiting | 9 | Taiwan Mitochondrion Applied Technology Co., Ltd. | 2026-03-01 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Parkinson's Disease are recruiting right now?
1 of 19 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Parkinson's Disease?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 19 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Parkinson's Disease?
1 of 19 records carry a Phase 3 or Phase 4 label and 4 are marked completed. Registrations run from 2009 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Parkinson's Disease: cell-therapy evidence and registered trials
- How much does stem cell therapy for Parkinson's Disease cost? (2026)
- Parkinson's Disease stem cell therapy — your questions answered (2026)
- Parkinson's Disease: cell-therapy evidence by therapy class
- MSC vs exosomes for Parkinson's Disease: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.